Evidence map›Paper›PMID 27769044›Full record

SynthesisOncotarget2016

Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.

Ran Ren, Pengpeng Yin, Yan Zhang, Jianyun Zhou, Yixing Zhou, Rufu Xu, Hai Lin, Chunji Huang

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Biomarkers in the diagnosis of pleural diseases: a 2018 update.Therapeutic advances in respiratory disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ran RenDivision of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Pengpeng YinDivision of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Yan ZhangDivision of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Jianyun ZhouDivision of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Yixing ZhouDivision of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Rufu XuDivision of Scientific Research, Xinqiao Hospital, Third Military Medical University, Chongqing, 400037, China.
Hai LinDepartment of Scientific Research, Third Military Medical University, Chongqing, 400038, China.
Chunji HuangDepartment of Scientific Research, Third Military Medical University, Chongqing, 400038, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral studies have investigated the diagnostic value of fibulin-3 for malignant pleural mesothelioma (MPM), but the results were various. Therefore, we performed a systematic review and meta-analysis to evaluate the diagnostic value of fibulin-3 for MPM.

resultsEight studies were included in this work. The overall sensitivity of blood fibulin-3 were 0.87 (95% CI, 0.58 - 0.97) and 0.89 (95% CI, 0.77 - 0.95), respectively. The overall sensitivity and specificity of PF fibulin-3 for MPM were 0.73 (95% CI, 0.54 - 0.86) and 0.80 (95% CI, 0.60 - 0.91), respectively. The area under curve of blood and pleural effusion (PF) Fibulin-3 were 0.94 (95% CI, 0.91 - 0.96) 0.83 (95% CI, 0.79 - 0.86), respectively.

methodsPubMed and EMBASE databases were searched up to July 29, 2016 to verify studies investigating the diagnostic value of fibulin-3 for MPM. The quality of eligible studies was assessed using the revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2). The overall sensitivity and specificity were pooled using a bivariate model.

conclusionFibuoin-3 is a useful diagnostic marker for MPM.

Indexed as

Biomarkers, TumorExtracellular Matrix ProteinsHumansLung NeoplasmsMesotheliomaMesothelioma, MalignantPleural NeoplasmsPredictive Value of TestsPrognosisSensitivity and SpecificityBiomarkers, TumorEFEMP1 protein, humanExtracellular Matrix Proteinsdiagnostic valueFibulin-3malignant pleural mesotheliomameta-analysissystematic review

Identifiers

PMID27769044
PMCPMC5356703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.